Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Status Not yet recruiting

Clinical Trial Summary

By prospectively observing the time to the best therapeutic effect of non-small cell lung cancer after ICI treatment, the characteristics of lesion distribution when the best therapeutic effect is reached, and the phenotype of disease progression after ICI treatment response, the investigators intended to explore the failure pattern of NSCLC after the once effective ICI treatment. The investigators also aim to evaluate the feasibility and clinical value of radiotherapy for the treatment of oligo-progressive lesions after ICI.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04492969
Study type	Observational [Patient Registry]
Source	Fudan University
Contact	Zhengfei Zhu, MD
Phone	+86-18017312901
Email	fuscczzf@163.com
Status	Not yet recruiting
Phase
Start date	September 1, 2020
Completion date	August 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05543330` - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	Phase 1/Phase 2
Recruiting	`NCT04106180` - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05215548` - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Recruiting	`NCT04116918` - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated	`NCT03411473` - Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2
Recruiting	`NCT03564197` - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC	N/A
Not yet recruiting	`NCT06219317` - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	Phase 2
Not yet recruiting	`NCT04604470` - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting	`NCT04136535` - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Completed	`NCT06339554` - Alectinib-induced Endocrine Toxicity
Active, not recruiting	`NCT04549428` - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2
Recruiting	`NCT04180501` - SRS Sequential Sindilimab in Brain Metastasis of NSLSC	Phase 2